# Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.

Study · id `cardio:ct-nct04654988` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04654988](<https://clinicaltrials.gov/study/NCT04654988>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04654988

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT04654988. Randomized; quadruple masking; primary purpose treatment. Start 2022-12-01 (actual); primary completion 2027-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT04654988, source copy `cardio:ctgov-nct04654988-2026-09-22`, retrieved 2026-10-26)
- Started: 2022-12-01 (actual) (ClinicalTrials.gov record NCT04654988, source copy `cardio:ctgov-nct04654988-2026-09-22`, retrieved 2026-10-26)
- Primary completion: 2027-09-30 (anticipated) (ClinicalTrials.gov record NCT04654988, source copy `cardio:ctgov-nct04654988-2026-09-22`, retrieved 2026-10-26)
- Completion: 2028-03-30 (anticipated) (ClinicalTrials.gov record NCT04654988, source copy `cardio:ctgov-nct04654988-2026-09-22`, retrieved 2026-10-26)
- Countries: Poland (ClinicalTrials.gov record NCT04654988, source copy `cardio:ctgov-nct04654988-2026-09-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04654988-2026-09-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.
- Acronym: IMPROVE-MC
- Condition: Myocarditis
- Condition: Heart Failure
- Condition: Endomyocardial Biopsy
- Condition: Cardiomyopathies, Secondary
- Condition: Immunosuppression
- Intervention (Drug): Prednisone
- Intervention (Drug): Azathioprine
- Intervention (Drug): Placebo Prednisone
- Intervention (Drug): Placebo Azathioprine
- Lead sponsor: Medical University of Warsaw
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Medical University of Warsaw (`cardio:org-medical-university-of-warsaw`)

## Provenance

Content hash: 6c22fff3926df25ee91c18375630134fe20c08398fb05204f13266e24219c356
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
